Piramal Imaging SA, a division of Piramal Enterprises, announced Ana M. Catafau, M.D., Ph.D., as vice president (VP) of Clinical Research and Development, Neurosciences. Dr. Catafau brings more than 20 years of experience in neuroimaging research with SPECT and PET both in academia and in the pharmaceutical industry. Her tenure includes 16 years with the University Hospitals Clinic and Sant Pau in Barcelona, and eight years at GlaxoSmithKline. Most recently, Dr. Catafau was the President and CEO of Barcelona Imaging Group, S.L. (BIG).
Dr. Catafau is an internationally recognized expert in the field of neuroimaging, having been the Chair of the European Association of Nuclear Medicine (EANM) Neuroimaging Committee, a member of the Journal of Nuclear Medicine Editorial Board and a member of scientific committees of international congresses. Her experience is backed up by her extensive scientific publication records, numerous grants, contracts, and scientific awards won related to her work with brain imaging.
Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. Piramal Imaging strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life threatening diseases leading to better therapeutic outcomes and improved quality of life.